Study of Triple Combination of Atezolizumab + Cobimetinib + Eribulin (ACE) in Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer

Condition:   Malignant Neoplasm of Breast Interventions:   Drug: Cobimetinib;   Drug: Atezolizumab;   Drug: Eribulin Sponsors:   M.D. Anderson Cancer Center;   Genentech, Inc. Not yet recruiting - verified June 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials